Concord Biotech Statistics

Total Valuation

Concord Biotech has a market cap or net worth of INR 210.16 billion. The enterprise value is 207.02 billion.

Market Cap	210.16B
Enterprise Value	207.02B

Important Dates

The next estimated earnings date is Wednesday, August 13, 2025.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	104.62M
Shares Outstanding	n/a
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	26.20M

Valuation Ratios

The trailing PE ratio is 56.55 and the forward PE ratio is 46.41.

PE Ratio	56.55
Forward PE	46.41
PS Ratio	17.51
PB Ratio	11.59
P/TBV Ratio	11.60
P/FCF Ratio	157.61
P/OCF Ratio	85.95
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 40.99, with an EV/FCF ratio of 155.25.

EV / Earnings	55.70
EV / Sales	17.25
EV / EBITDA	40.99
EV / EBIT	45.94
EV / FCF	155.25

Financial Position

The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.00.

Current Ratio	6.17
Quick Ratio	4.56
Debt / Equity	0.00
Debt / EBITDA	0.01
Debt / FCF	0.02
Interest Coverage	853.88

Financial Efficiency

Return on equity (ROE) is 22.26% and return on invested capital (ROIC) is 16.85%.

Return on Equity (ROE)	22.26%
Return on Assets (ROA)	15.13%
Return on Invested Capital (ROIC)	16.85%
Return on Capital Employed (ROCE)	24.43%
Revenue Per Employee	8.72M
Profits Per Employee	2.70M
Employee Count	1,377
Asset Turnover	0.64
Inventory Turnover	1.87

Taxes

In the past 12 months, Concord Biotech has paid 1.23 billion in taxes.

Income Tax	1.23B
Effective Tax Rate	24.85%

Stock Price Statistics

The stock price has increased by +19.22% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+19.22%
50-Day Moving Average	1,684.02
200-Day Moving Average	1,896.39
Relative Strength Index (RSI)	66.90
Average Volume (20 Days)	13,341

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Biotech had revenue of INR 12.00 billion and earned 3.72 billion in profits. Earnings per share was 35.52.

Revenue	12.00B
Gross Profit	7.82B
Operating Income	4.52B
Pretax Income	4.95B
Net Income	3.72B
EBITDA	5.06B
EBIT	4.52B
Earnings Per Share (EPS)	35.52

Full Income Statement

Balance Sheet

The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion.

Cash & Cash Equivalents	3.18B
Total Debt	29.69M
Net Cash	3.15B
Net Cash Per Share	n/a
Equity (Book Value)	18.13B
Book Value Per Share	173.28
Working Capital	9.51B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.45 billion and capital expenditures -1.11 billion, giving a free cash flow of 1.33 billion.

Operating Cash Flow	2.45B
Capital Expenditures	-1.11B
Free Cash Flow	1.33B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.19%, with operating and profit margins of 37.66% and 30.97%.

Gross Margin	65.19%
Operating Margin	37.66%
Pretax Margin	41.21%
Profit Margin	30.97%
EBITDA Margin	42.19%
EBIT Margin	37.66%
FCF Margin	11.11%

Dividends & Yields

Concord Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	24.63%
Buyback Yield	-0.01%
Shareholder Yield	n/a
Earnings Yield	1.77%
FCF Yield	0.63%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	4